Diabetes

The NHS Long Term Plan announced, on March 7, 2019, that the NHS will ensure that patients with type 1 diabetes will benefit from life changing flash glucose monitors from April 2019. This will end the variation patients in some parts England are facing. The new guidance sets out the criteria for flash glucose monitoring and the maximum amounts CCGs will be reimbursed for the ongoing costs of the flash glucose sensors.

On the Interterritorial Council that took place March 4th, 2019, the Working Plan for the Spanish Network for Health Technology Assessment was agreed and published. The working plan includes 22 health technology assessment reports, 7 monitoring studies, 9 clinical practice guidelines, and 1 evidence-based product.

In January 2019, the National Institute for Health and Care Excellence (NICE) published six new interventional procedure guidance, three medical technologies guidance, and three new MedTech innovation briefings for liver function capacity test, a functional electrical stimulation (FES) integrated cycling system used to start muscle contraction to stimulate trunk and limb muscles in people with spinal cord injury, laser shoe attachment used as a walking aid and is designed to help prevent freezing of gait in people with Parkinson's disease.

In September, the National Institute for Health and Care Excellence (NICE) published two new interventional procedure guidance for transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia and intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer, one medical technologies guidance for neuropad for detecting preclinical diabetic peripheral neuropathy and two new medtech innovation.

The French National Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in the period July-September 2018 concern various types of devices. In total, 52 decisions were published.

At the end of June of 2018, the Federal Joint Committee (G-BA) has commissioned to the Institute for Quality and Efficiency in Health Care (IQWiG) to provide an update of the Disease Management Program (DMP) for Diabetes Mellitus type 2 in order to perform a systematic research, make a selection of guidelines based on methodological criteria and extract guideline recommendations relevant for the treatment of Diabetes Mellitus type 2. The final report is expected to be released on the 31st of December, 2019.

On the 14th of May of 2018, Norwegian RHF Decision Forum (Beslutningsforum) has recommended usage of the Flash Glucose Monitoring system - Freestyle Libre for the treatment and follow-up of children (less than 18 years) with type 1 diabetes and other types of diabetes.

During the last meeting of the Interterritorial Council of the National Health System in Spain (end of April) three decisions about coverage or new services or indications in the National Benefit Catalogue were announced. They concern hearing aids, micropigmentation of the nipples and continuous glucose monitoring. The changes are still due to be formalized in a form of a Royal Decree.

On 11th May, the Italian Ministry of Health announced from its website that five new Med Tech-related HTA documents are available for public consultation. See the details in the MTRC post.

Flash Glucose Monitoring (FGM) is covered care for four groups of diabetic patients who are already eligible for reimbursement of real-time continuous glucose monitoring (RTCGM). This is stated in the 'Flash Glucose Monitoring' assesement of the Dutch National Health Care Institute

NHS England has announced expansion of the NHS Diabetes Prevention Programme to cover another 25% of the population (Wave 2) in addition to the program, which has already covered about 50% of the population (Wave 1) and which was started last year. NHS Diabetes Prevention Programme is the program in England, which connects existing elements of health care system focused on prevention of diabetes and additional element of behavioral intervention for nondiabetic hyperglycaemia into a comprehensive program aimed on prevention of diabetes type II.